Gastroenteropancreatic Neuroendocrine Tumors-Current Status and Advances in Diagnostic Imaging

Diagnostics (Basel). 2023 Aug 23;13(17):2741. doi: 10.3390/diagnostics13172741.

Abstract

Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) is a heterogeneous and complex group of tumors that are often difficult to classify due to their heterogeneity and varying locations. As standard radiological methods, ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET/CT) are available for both localization and staging of NEN. Nuclear medical imaging methods with somatostatin analogs are of great importance since radioactively labeled receptor ligands make tumors visible with high sensitivity. CT and MRI have high detection rates for GEP-NEN and have been further improved by developments such as diffusion-weighted imaging. However, nuclear medical imaging methods are superior in detection, especially in gastrointestinal NEN. It is important for radiologists to be familiar with NEN, as it can occur ubiquitously in the abdomen and should be identified as such. Since GEP-NEN is predominantly hypervascularized, a biphasic examination technique is mandatory for contrast-enhanced cross-sectional imaging. PET/CT with somatostatin analogs should be used as the subsequent method.

Keywords: computed tomography; gastroenteropancreatic neuroendocrine neoplasia; magnetic resonance imaging; metastasis; positron emission computed tomography; sensitivity.

Publication types

  • Review

Grants and funding

This research received no external funding.